Literature DB >> 18612800

CD133 identifies perivascular niches in grade II-IV astrocytomas.

Karina Christensen1, Henrik D Schrøder, Bjarne W Kristensen.   

Abstract

The aim of the present study was to investigate the localization and distribution of the putative brain tumour stem cell marker CD133 in formalin fixed paraffin embedded astrocytomas. A retrospective analysis of 114 grade II, III and IV astrocytomas was undertaken. The immunohistochemical expression of CD133 in paraffin sections was analysed using morphometry. In all grades, CD133 was expressed on tumour and endothelial cells. Tumour cells were found in perivascular niches, as dispersed single cells and in pseudopalisade formations around necrosis. There was no correlation between the mean volume fraction of CD133(+) niches and all CD133(+) tumour cells and tumour grade. However, the volume fraction of CD133(+) blood vessels increased significantly from 0.4% in diffuse astrocytomas to 2.2% in glioblastomas. Neither of them was related to patient survival. Double immunofluorescence stainings showed that the CD133(+) niches both contained CD133(+) cells with and without co-expression of the intermediate filament protein marker nestin, and only few CD133(+)/MIB-1(+) proliferating cells were found. In conclusion, a CD133(+) perivascular stem cell-like entity exists in astrocytomas. CD133(+) tumour vessels may play an important role in a brain tumour stem cell context, while CD133 alone does not appear to be a specific tumour stem cell marker related to patient survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18612800     DOI: 10.1007/s11060-008-9648-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  48 in total

1.  Vascular niche for adult hippocampal neurogenesis.

Authors:  T D Palmer; A R Willhoite; F H Gage
Journal:  J Comp Neurol       Date:  2000-10-02       Impact factor: 3.215

2.  Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer.

Authors:  Eva Fernebro; Michael Dictor; Pär-Ola Bendahl; Mårten Fernö; Mef Nilbert
Journal:  Arch Pathol Lab Med       Date:  2002-06       Impact factor: 5.534

3.  Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer.

Authors:  Mareike Florek; Michael Haase; Anne-Marie Marzesco; Daniel Freund; Gerhard Ehninger; Wieland B Huttner; Denis Corbeil
Journal:  Cell Tissue Res       Date:  2004-11-19       Impact factor: 5.249

4.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.

Authors:  Catherine A O'Brien; Aaron Pollett; Steven Gallinger; John E Dick
Journal:  Nature       Date:  2006-11-19       Impact factor: 49.962

5.  Validation of tissue microarray technology in ovarian carcinoma.

Authors:  Daniel G Rosen; Xuelin Huang; Michael T Deavers; Anais Malpica; Elvio G Silva; Jinsong Liu
Journal:  Mod Pathol       Date:  2004-07       Impact factor: 7.842

6.  Evaluation of the value of frozen tissue section used as "gold standard" for immunohistochemistry.

Authors:  Shan-Rong Shi; Cheng Liu; Llana Pootrakul; Laurie Tang; Andrew Young; Ryan Chen; Richard J Cote; Clive R Taylor
Journal:  Am J Clin Pathol       Date:  2008-03       Impact factor: 2.493

7.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.

Authors:  T Lapidot; C Sirard; J Vormoor; B Murdoch; T Hoang; J Caceres-Cortes; M Minden; B Paterson; M A Caligiuri; J E Dick
Journal:  Nature       Date:  1994-02-17       Impact factor: 49.962

8.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

9.  Stem cell marker CD133 affects clinical outcome in glioma patients.

Authors:  Felix Zeppernick; Rezvan Ahmadi; Benito Campos; Christine Dictus; Burkhard M Helmke; Natalia Becker; Peter Lichter; Andreas Unterberg; Bernhard Radlwimmer; Christel C Herold-Mende
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

10.  Cancerous stem cells can arise from pediatric brain tumors.

Authors:  Houman D Hemmati; Ichiro Nakano; Jorge A Lazareff; Michael Masterman-Smith; Daniel H Geschwind; Marianne Bronner-Fraser; Harley I Kornblum
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-26       Impact factor: 11.205

View more
  49 in total

1.  CD133+ niches and single cells in glioblastoma have different phenotypes.

Authors:  Karina Christensen; Henrik Daa Schrøder; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2010-12-24       Impact factor: 4.130

2.  Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.

Authors:  Sarah J Conley; Elizabeth Gheordunescu; Pramod Kakarala; Bryan Newman; Hasan Korkaya; Amber N Heath; Shawn G Clouthier; Max S Wicha
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

Review 3.  Glioblastoma niches: from the concept to the phenotypical reality.

Authors:  Davide Schiffer; Marta Mellai; Enrica Bovio; Ilaria Bisogno; Cristina Casalone; Laura Annovazzi
Journal:  Neurol Sci       Date:  2018-05-08       Impact factor: 3.307

4.  Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells.

Authors:  Yuanyan Wei; Yizhou Jiang; Fei Zou; Yingchao Liu; Shanshan Wang; Nuo Xu; Wenlong Xu; Chunhong Cui; Yang Xing; Ying Liu; Benjin Cao; Chanjuan Liu; Guoqiang Wu; Hong Ao; Xiaobiao Zhang; Jianhai Jiang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-08       Impact factor: 11.205

5.  Clinical value of CD133 and nestin in patients with glioma: a population-based study.

Authors:  Rikke H Dahlrot; Steinbjørn Hansen; Stine S Jensen; Henrik D Schrøder; Jacob Hjelmborg; Bjarne W Kristensen
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

6.  The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma.

Authors:  Michael Karsy; Ladislau Albert; Raj Murali; Meena Jhanwar-Uniyal
Journal:  Tumour Biol       Date:  2014-01-08

Review 7.  What is the clinical value of cancer stem cell markers in gliomas?

Authors:  Rikke Hedegaard Dahlrot; Simon Kjær Hermansen; Steinbjørn Hansen; Bjarne Winther Kristensen
Journal:  Int J Clin Exp Pathol       Date:  2013-02-15

8.  Brain Tumor Stem-Like Cells Identified by Neural Stem Cell Marker CD15.

Authors:  Xing-Gang Mao; Xiang Zhang; Xiao-Yan Xue; Geng Guo; Peng Wang; Wei Zhang; Zhou Fei; Hai-Ning Zhen; Si-Wei You; Hao Yang
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

9.  Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.

Authors:  Juan L Garcia; Maria Perez-Caro; Juan A Gomez-Moreta; Francisco Gonzalez; Javier Ortiz; Oscar Blanco; Magdalena Sancho; Jesus M Hernandez-Rivas; Rogelio Gonzalez-Sarmiento; Manuel Sanchez-Martin
Journal:  BMC Cancer       Date:  2010-08-24       Impact factor: 4.430

10.  Expression and Distribution Characteristics of Human Ortholog of Mammalian Enabled (hMena) in Glioma.

Authors:  Xue-Tao Dong; Xue-Jun Yang; Hua-Min Wang; Wei Wang; Li Yu; Bin Zhang; Sheng-Ping Yu; Hao-Lang Ming
Journal:  Chin J Cancer Res       Date:  2011-12       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.